Abstract
Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn's disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the effi cacy of infliximab in the treatment of moderate to severe UC.
| Original language | English |
|---|---|
| Pages (from-to) | 379-388 |
| Number of pages | 10 |
| Journal | Biologics: Targets and Therapy |
| Volume | 2 |
| Issue number | 3 |
| State | Published - 2008 |
| Externally published | Yes |
Keywords
- Anti-TNF-α
- Antibody
- Crohn's disease
- Infliximab
- Ulcerative colitis
Fingerprint
Dive into the research topics of 'Infliximab in ulcerative colitis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver